Cessatech (CESSA) Q3 2025 earnings summary

Executive summary

• Achieved key milestones including completion of CT001 clinical and regulatory activities and submission of the MAA to EMA, positioning for potential approval by end of 2026.

• US manufacturing technology transfer for CT001 completed, enabling first commercial batches and robust supply chain for US market launch.

• Focused on organizational development and commercial launch planning with partners.

Financial highlights

• Q3 2025 net revenue was DKK 1,243 thousand; net loss for the period was DKK 3,050 thousand.

• Operating loss for Q3 2025 was DKK 3,967 thousand, reflecting finalization of clinical and regulatory activities.

• Cash at bank at period end was DKK 9,090 thousand.

• Earnings per share for Q3 2025 was DKK -0.16.

• Solidity (solvency ratio) stood at 84% as of 30 September 2025.

Outlook and guidance

• EMA review for CT001 expected to take 9–12 months, with potential approval by end of 2026.

• US Early Access Program for CT001 anticipated to improve revenue potential.

• Expenses expected to decrease until new development activities are initiated.